Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
about
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreating refractory leukemias in childhood, role of clofarabineMyeloid leukemia in Down syndromeTransient Abnormal Myelopoiesis and AML in Down Syndrome: an UpdateMicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathwaysIdarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in KoreaClassification of pediatric acute myeloid leukemia based on miRNA expression profiles.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study.The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international studySurvival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplantGlobal characteristics of childhood acute promyelocytic leukemia.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaIncidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsCollaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology GroupOutcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelaeAllogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapyClinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.Combating blood stream infections during induction chemotherapy in children with acute myeloid leukemia: Single center results in India.Diagnostic & prognostic role of microRNAs in paediatric acute myeloid leukaemia.Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India.
P2860
Q24187297-54DEA520-3D78-40C3-AAA7-F5990804D09EQ24193790-F8A8A940-7A23-4805-BC35-85E761A7BA9AQ24234833-761E4DA4-6D99-4EA7-AE07-97D07A8FF712Q24241602-55DC64EE-6767-4733-B285-D7F2026C48A6Q24647279-68640F41-C949-43FE-A907-7F57937D3E93Q27027258-8A04F731-7FAA-4638-BE1D-7E3214DE740FQ28079980-BB00B4DB-5A0D-4053-B787-093B58C97553Q28486136-E1D50F0E-2B70-416C-B8BC-0331D6B16921Q33565514-6234F17D-504C-434A-8C4B-77B45DC12D04Q33779361-2F4EC17C-407E-4D83-A5C3-FFB4384AE4B1Q34080807-494DCC3C-1EB0-48EC-85D3-72A38DF40A1CQ34325487-03EC03C4-69D3-4ADC-B244-141CD22D1C13Q34344493-E29A52F3-90B1-4C16-BEE7-A18DE59965E8Q34764504-BF4E9BBF-073A-4E91-AFF9-0F009F639F47Q35040531-22EDA926-E024-4FD7-A512-5E2ED2C44CB7Q35127974-77E0A7F3-09A7-4BB6-928D-DDF3D1ADC365Q35189037-CC5F6C09-DB5F-4D66-8D43-B8D2346E8882Q35231673-A899EE6E-C3F6-4B1B-9961-94A8EE52D05CQ35265916-FF68DC90-9182-4B3D-8818-64A51A98293CQ35563658-BC841F74-E5B6-4F5F-920F-4F6C65E33A4EQ35568696-F0BF2A0C-49A7-4876-AB6B-C99E70632442Q36053792-F1CBCB33-7C7A-40AC-A6CD-770898F6E47BQ36366665-C32A0AF5-4921-4D6E-AE38-C828F040919AQ36407162-6DDBB569-4EAE-48FD-9A12-1028BDE2CF29Q36661874-F8ECDB9D-031B-4117-8E59-33D42FBFE629Q37017217-494241BD-6417-4DA0-AF60-3B8D41601D43Q37121665-3D56C80D-D05C-4236-9885-02B5E396E16AQ37323006-4E73F276-F05A-4449-B10C-BFF14EC306FCQ37364550-DC9A1372-3D3D-4951-BB22-6B8B0462142BQ37874929-B2B2A438-FCF2-45D0-BAE1-12628C2C6536Q38097334-7FD4EA97-C7DD-4D4E-A48F-40B069676913Q38112088-698FB215-9BF0-4178-B544-ACA19A9805FCQ38155455-106EB6AC-EB16-40DE-BDE7-276C12D202C5Q38196743-0C9B66AD-BF1C-48C8-A87E-29C1D15332E0Q38205864-42B9ED69-536A-4C14-8A33-F968E3B21BE4Q38345216-53B2AFCC-4A96-4F0C-BB09-3634647C3B88Q38884168-B7E844C6-CB33-43F9-9DEB-2ECAE0138983Q39285462-A6EFC90F-5D71-448B-B609-46BF853FF016Q39477447-0F8CC090-7977-4E2E-9E59-60FD72459093Q39589791-DDEF4904-5988-40EB-A400-8BC8F6A246DA
P2860
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Treatment strategies and long- ...... ur consecutive AML-BFM trials.
@en
type
label
Treatment strategies and long- ...... ur consecutive AML-BFM trials.
@en
prefLabel
Treatment strategies and long- ...... ur consecutive AML-BFM trials.
@en
P2093
P2860
P356
P1433
P1476
Treatment strategies and long- ...... ur consecutive AML-BFM trials.
@en
P2093
Creutzig U
Reinhardt D
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403920
P577
2005-12-01T00:00:00Z
P5875
P6179
1038093844